Malignant effusions and immunogenic tumour-derived exosomes - PubMed (original) (raw)
. 2002 Jul 27;360(9329):295-305.
doi: 10.1016/S0140-6736(02)09552-1.
Noel E C Schartz, Mojgan Movassagh, Caroline Flament, Patricia Pautier, Philippe Morice, Christophe Pomel, Catherine Lhomme, Bernard Escudier, Thierry Le Chevalier, Thomas Tursz, Sebastian Amigorena, Graca Raposo, Eric Angevin, Laurence Zitvogel
Affiliations
- PMID: 12147373
- DOI: 10.1016/S0140-6736(02)09552-1
Malignant effusions and immunogenic tumour-derived exosomes
Fabrice Andre et al. Lancet. 2002.
Abstract
Background: Exosomes derived from tumours are small vesicles released in vitro by tumour cell lines in culture supernatants. To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells.
Methods: We isolated exosomes by ultracentrifugation on sucrose and D(2)O gradients of 11 malignant effusions. We characterised exosomes with Western blot analyses, immunoelectron microscopy, and in-vitro stimulations of autologous T lymphocytes.
Findings: Malignant effusions accumulate high numbers of membrane vesicles that have a mean diameter of 80 nm (SD 30). These vesicles have antigen-presenting molecules (MHC class-I heat-shock proteins), tetraspanins (CD81), and tumour antigens (Her2/Neu, Mart1, TRP, gp100). These criteria, including their morphological characteristics, indicate the similarities between these vesicles and exosomes. Exosomes from patients with melanoma deliver Mart1 tumour antigens to dendritic cells derived from monocytes (MD-DCs) for cross presentation to clones of cytotoxic T lymphocytes specific to Mart1. In seven of nine patients with cancer, lymphocytes specific to the tumour could be efficiently expanded from peripheral blood cells by pulsing autologous MD-DCs with autologous ascitis exosomes. In one patient tested, we successfully expanded a restricted T-cell repertoire, which could not be recovered carcinomatosis nodules.
Interpretation: Exosomes derived from tumours accumulate in ascites from patients with cancer. Ascitis exosomes are a natural and new source of tumour-rejection antigens, opening up new avenues for immunisation against cancers.
Comment in
- Tumour antigens on tap.
Ronchese F, Prasad S, Ritchie DS. Ronchese F, et al. Lancet. 2002 Jul 27;360(9329):268. doi: 10.1016/S0140-6736(02)09560-0. Lancet. 2002. PMID: 12147364 No abstract available. - Findings of Research Misconduct.
[No authors listed] [No authors listed] Fed Regist. 2022 Nov 28;87(227):73007-73009. Fed Regist. 2022. PMID: 36468084 Free PMC article. No abstract available.
Similar articles
- Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment.
Li QL, Bu N, Yu YC, Hua W, Xin XY. Li QL, et al. Clin Med Oncol. 2008;2:461-7. doi: 10.4137/cmo.s776. Epub 2008 Jun 11. Clin Med Oncol. 2008. PMID: 21892318 Free PMC article. - Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L. André F, et al. J Immunol. 2004 Feb 15;172(4):2126-36. doi: 10.4049/jimmunol.172.4.2126. J Immunol. 2004. PMID: 14764678 - [Tumour-derived exosomes and their roles in cancer].
Wang K, Tang J. Wang K, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Dec;35(12):1288-92. doi: 10.3969/j.issn.1672-7347.2010.12.015. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010. PMID: 21200099 Review. Chinese. - Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells.
Radford KJ, Jackson AM, Wang JH, Vassaux G, Lemoine NR. Radford KJ, et al. Int J Cancer. 2003 Jul 20;105(6):811-9. doi: 10.1002/ijc.11149. Int J Cancer. 2003. PMID: 12767067 - The potential of exosomes in immunotherapy.
Chaput N, Taïeb J, André F, Zitvogel L. Chaput N, et al. Expert Opin Biol Ther. 2005 Jun;5(6):737-47. doi: 10.1517/14712598.5.6.737. Expert Opin Biol Ther. 2005. PMID: 15952905 Review.
Cited by
- Exosomes: Key Factors in Ovarian Cancer Peritoneal Metastasis and Drug Resistance.
Shao M, Gao Y, Xu X, Chan DW, Du J. Shao M, et al. Biomolecules. 2024 Sep 2;14(9):1099. doi: 10.3390/biom14091099. Biomolecules. 2024. PMID: 39334866 Free PMC article. Review. - MAP kinase kinase 1 (MEK1) within extracellular vesicles inhibits tumour growth by promoting anti-tumour immunity.
Searles SC, Chen WS, Yee JD, Lee P, Lee CK, Caron C, Neto F, Matei I, Lyden D, Bui JD. Searles SC, et al. J Extracell Vesicles. 2024 Oct;13(10):e12515. doi: 10.1002/jev2.12515. J Extracell Vesicles. 2024. PMID: 39330930 Free PMC article. - Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.
Din MAU, Wan A, Chu Y, Zhou J, Yan Y, Xu Z. Din MAU, et al. Front Med (Lausanne). 2024 Jul 30;11:1406547. doi: 10.3389/fmed.2024.1406547. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39139783 Free PMC article. Review. - Current advance of nanotechnology in diagnosis and treatment for malignant tumors.
Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Wang B, et al. Signal Transduct Target Ther. 2024 Aug 12;9(1):200. doi: 10.1038/s41392-024-01889-y. Signal Transduct Target Ther. 2024. PMID: 39128942 Free PMC article. Review. - Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells.
Schioppa T, Gaudenzi C, Zucchi G, Piserà A, Vahidi Y, Tiberio L, Sozzani S, Del Prete A, Bosisio D, Salvi V. Schioppa T, et al. J Transl Med. 2024 Jul 29;22(1):691. doi: 10.1186/s12967-024-05457-4. J Transl Med. 2024. PMID: 39075551 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous